cannabinoids - sdm · medical cannabis takes big bite out of pharmaceutical sales: 1 cannabis can...
TRANSCRIPT
STARSEED IS…A GLOBAL CANNABIS COMPANY
Medical CannabisDr. Peter M. Blecher, M.D.,C.M, DAAPM, DCAPM
Chief Medical OfficerStarseed Medicinal, Inc.
Medical DirectorCPM Centre for Pain Management
cannabinoids & the elephant in the room
history science, safety & evidence
societal costs workplace impact
cost-savings to society & benefit plans
emerging insurance coverage2
Used since antiquity for healing and medical powers
Only in 19th century, powerful and emerging tobacco lobby had cannabis production restricted, and then criminalized
In the U.S., became seen as drug of choice for the marginalized… social stigma, and way to ‘control’ these groups
Complete ban on production at start of last century; exception of WW I-II, where Congress temporarily allowed massive hemp production during war effort:
hemp by far most robust material for ropes, sails and paper word ‘canvas’ in fact, is derived from ‘cannabis’
Since end of WWII, ongoing politicized fight in West3
Cannabinoids are compounds that act on cannabinoid receptors naturally found in the human body
Endocannabinoids are cannabinoids that are naturally produced in the body
Phytocannabinoids are cannabinoids produced by the cannabis plant
4
Synthetic Cannabinoids(Made in a lab)
Endocannabinoid Receptors
(brain & immune cells)
Phytocannabinoids(Produced by plants)
Endocannabinoids(Naturally made in the body)
5
-
-
6
Signaling system
Important regulatory functions involved in:
Pain Appetite & digestion Sleep-wake cycle Psychiatric disease
… just to mention a few
7
Ref: www.CCIC.net8
Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000 Dec;60(6):1303-14. Review. PubMed PMID: 11152013.
Cannabis 1000:1Diazepam 100:1Morphine 70:1Cocaine 15:1Alcohol 10:1Digoxin 2:1
9
“A smoker would theoretically have to consume nearly 1,500 of cannabis within fifteen
minutes to induce a lethal dose”
The Report of the National Commission on Marihuana and Drug Abuse; Marihuana: A Signal of MisunderstandingCommissioned by President Richard M. Nixon, March, 1972
10
Cannabis (Sativa, Indica, or Ruderalis)
‘Marijuana’ (dried leaves and flowering heads)
Isolated pure compounds
Cannabinoids
Psychoactive
Δ8-THC cannabinol (weak)
Inactive >60 compounds
Kalant 2001
Non-cannabinoids:
Non-psychoactive
11
12
100+ cannabinoids
350+ terpenes / flavonoids
Fast onset of action when inhaled – shorter duration
Slower onset of action when ingested – longer duration
A theory that all the various compounds present in the plant work together in a cooperative manner to yield the best results1
1 Russo, E. B. (2011), Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163: 1344–1364
13
Δ9-THC the receptors
Causes psychoactive effects of cannabis
Effective for relief of chronic nerve pain, muscle spasms, controlling nausea and stimulating appetite
CBD receptor activity
Not psychoactive and does Notcause sedation
Anti-inflammatory, possible pain killer, may help with nausea, vomiting, seizures, anxiety and depression
Appears to opioid reward1
1 Lucas, P, Walsh, Z, et al; Substituting Cannabis for Prescription Drugs, alcohol and other substances among Medical Patients:The impact of Contextual Factors. Drug Alcohol Review; 2016 May; 35(3):326-33
14
Δ9-THC the receptors
Causes psychoactive effects of cannabis
Effective for relief of chronic nerve pain, muscle spasms, controlling nausea and stimulating appetite
CBD receptor activity
Not psychoactive and does Notcause sedation
Anti-inflammatory, possible pain killer, may help with nausea, vomiting, seizures, anxiety and depression
1 Lucas, P, Walsh, Z, et al; Substituting Cannabis for Prescription Drugs, alcohol and other substances among Medical Patients:The impact of Contextual Factors. Drug Alcohol Review; 2016 May; 35(3):326-33
The ratio of (cannabidiol) to (tetrahydrocannabinol) in the plant influences the therapeutic effects
15
Chronic musculoskeletal & neuropathic pain
Arthritic inflammation
IBS / IBD
Certain anxiety, PTSD and sleep disorders
Seizures (Dravet Syndrome)
Further information available in Health Canada’s document “Information for Health Care Professionals: Cannabis and the Cannabinoids”
16
Nausea and vomiting due to chemotherapy (CINV)
Anorexia due to HIV or other treatments
Appetite stimulant
Motor disorders (Parkinson’s, Huntington's, Tourette’s)
Spasticity due to MS
Further information available in Health Canada’s document “Information for Health Care Professionals: Cannabis and the Cannabinoids”
17
Heart rate / rhythm Peripheral circulation Myocardial infarction (?) Stroke
Health Canada's document Information for Health Care Professionals; Cannabis (marihuana, marijuana) and the cannabinoids
Respiratory Psychiatric Neurocognitive Carcinogenic Gastrointestinal Reproductive
18
1 Reis JP, Auer R, Bancks MP, et al. Cumulative lifetime Marijuana use and incident cardiovascular disease in middle age: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Public Health 2017; 107 (4):601-606
Among younger individuals, does more than 25 years of cannabis use increase the risk of developing coronary artery disease?
This well-done government-funded, population-based, (prospective) cohort study, took into account traditional risk factors, did not find an association between chronic cannabis use and cardiovascular events
19
Recent study on opiate abuse looking at health data reported by large insured U.S. employers1
According to CDC, 2M Americans abuse opiates2
16,000 die every year from Rx opiate OD3
Sales of opiate Rx in U.S. ∧4x from 1999 – 20104
259M opiate Rx written in 2012 – enough for every American adult to have their own bottle5
1. Castlight Health commissioned report. “The Opiate Crisis in America’s Workforce”. 20162. Centers for Disease control and Prevention (CDC); Prescription Opiate Data 3. CDC. Opioid Data Analysis (2013). 4. CDC. Morbidity and Mortality Weekly Report. 5. CDC. Opioid Painkiller Prescribing.
Simply put – prescription crisis is getting , not better
20
21
47,055 people died of accidental drug overdose
29,467 from opioid-related drugs, including Rx meds
Overdose now leading cause of accidental death
4/5 who become addicted start out with a legal Rx
Substance-abuse disorders affect 20.8M Americans
22
Cannabinoids exhibit analgesic effects and potentiate the anti-nociceptive effects of opioids
Animal models demonstrate THC greatly enhancesanalgesic effects of morphine in a synergistic fashion
Reports suggest in opiate use, when synergistically using cannabinoids
Dr. Oz… “reefer rehab”
Health Canada's document Information for Health Care Professionals; Cannabis (marihuana, marijuana) and the cannabinoids 23
Opiate abuse costs the U.S. economy nearly $56B1
Opiate abuse costs employers $10B from absenteeism – 2
1. American Society of Addiction Medicine (ASAM). Cited in: Workforce. “Pain Points”. 2. Ibid 3. Ibid
Opiate-addicted employees cost employers that of non-addicted employees in overall benefit costs3
24
Spring 2017....
1 Volkov, N.D., Collins, F.S., The Role of Science in Addressing The Opioid Crisis. ‘Special Report’; NEJM. May 31, 2017:1-4
Opioid misuse and addiction is an ongoing and rapidly evolving public health crisis, requiring innovative scientific solutions… in response, NIH is joining with private partners… to find innovative medications and technologies to treat opioid addiction… [and] to manage chronic pain…
25
Medical cannabis takes big bite out of pharmaceutical sales: 1
Cannabis can be effective Sx treatment for conditions such as , , , , ,
, , , and …2
Americans spent on Rx medication to treat the above conditions in 2016
expected to grow to
1. New Frontier Data: Cannabis Sales Impact Big Pharma; May 21st, 20172. National Academies of Science
26
Three conditions drove highest Rx drug spend in 2016: 1
chronic pain ($14.3 billion) PTSD ($10.6 billion) sleep disorders ($6.13 billion)
The Rx drug use for these, falls an average of 11% in States with legalized medical cannabis
And keep in mind… there is coverage for medical cannabis in ANY of these jurisdictions - this is ALL 100% out-of-pocket by patients themselves!…
1. New Frontier Data: Cannabis Sales Impact Big Pharma; May 21st, 201727
If medical cannabis legalized nationally, 11% decline in overall Rx drug use equates to estimated $4.4 billion in reduced Rx spend -
Between 2016 and 2020, 11% reduction in Rx drug spending would be a
Again – this is without ANY federal, state, or third party coverage for medical cannabis
28
Implementation of medical cannabis laws has reduced opioid prescribing in US jurisdiction where it occured1
Rx filled for opioids decreased by 2.11 million annualized doses
And this is based on populationo again – NO coverage for cannabiso population with little disposable income
1. JAMA Int. Med. Published online April 2, 2018 29
- Comprehensive review of clinical, peer-reviewed literature by NASEM determined that:
“conclusive evidence” that cannabis can be used to treat chronic pain
cannabis use rising fastest in population >50 y.o. – group most likely to have the conditions for which evidence for cannabis benefits is strongest
1. National Academies of Sciences, Engineering, and Medicine; January 201730
Cannabis intoxication, like with potentially sedating or psychoactive substance, can affect and impair judgment and coordination, memory, learning, and attention
Cannabis as ‘medicine’ should be conflated with being impaired at work
31
Cannabis intoxication, like with potentially sedating or psychoactive substance, can affect and impair judgment and coordination, memory, learning, and attention
Whether prescription or otherwise, agent can be abused: Gravol®, Benadryl® and Tylenol®
… overdose deaths seen daily in ERs
32
Cannabis intoxication, like with potentially sedating or psychoactive substance, can affect and impair judgment and coordination, memory, learning, and attention
Imodium® - “poor-man’s methadone”… the “lope cocktail”
33
Compared to Alcohol – observed differences in ‘judgment impairment’…alcohol appears significantly worse 1
One can test positive days or weeks after useo Cannabis impacts individuals differently o THC levels do not correspond accurately with impairment levelso You cannot predict a person’s impairment level based on THC level
Like other psychoactive medications – titration and ‘steady state’ is critical…
1 Cannabis & Cannabis Resin: Pre-Review Report. World Health Organization Expert Committee on Drug Dependence. 38th meeting. Geneva Report; 14-18 November, 2016
34
In studies use, MVA Odds Ratio (OR) for DACU is ; that is, an 18% increase risk
This compares to an MVA OR of for a BAC >50 mg/dL, which is considered an acceptable BAC… that is …. - deemed
1 Capler, R., Bilsker, D., Van Pelt, K., & MacPherson, D. Cannabis Use and Driving: Evidence Review; Canadian Drug Policy Coalition (CDPC);Simon Fraser University; January 31, 2017
35
The rate of cannabis-related driving offences in Canada remains low, in comparison to those related to alcohol 1
Widely publicized results of large case-controlled observational study by the National Highway Traffic Safety Association in the U.S. in 2015 did find an increased rate of MVAs in drivers who had used cannabis 2
1 Cannabis & Cannabis Resin: Pre-Review Report. World Health Organization Expert Committee on Drug Dependence. 38th meeting. Geneva Report; 14-18 November, 2016
2 Compton, R., Berning, A. Drug and Alcohol Crash Risk. 2015 Feb. (Traffic Safety Facts Research Note. DOT HS 812 117).Washington, DC: National Highway Traffic Safety Association
36
Recently published meta-analysis of US traffic fatalities from 1985 –2014, and their relationship to medical marijuana laws (MMLs) using data from the 1
On Average, MML States had traffic fatalities than non-MML states
MMLs were associated with reductions in traffic fatalities in
1 Santaella-Tenorio, J., Mauro, CM, et al; ‘US Traffic Fatalities, 1985 – 2014, and Their Relationship to Medical Marijuana Laws”A J P bli H lth 2017 F b 107(2) 336 342
37
Focus should be on , and (in specific and limited circumstances) vaporization, and not on “lighting plants on fire”….
This is the future of cannabis as medicine…
38
Focus should be on , and (in specific and limited circumstances) vaporization, and not on “lighting plants on fire”….
is…
39
Multiple taskforces have debunked Cannabis as ‘gateway drug’ Poverty & poor social connectivity is gateway1
Is Cannabis addiction even possible?...
1 Lopez-Quintero, Perez de los Cobos, Jose, Hasin, D.S et al (2011). Probability and predictors of transition from first time use to dependenceon nicotine alcohol, cannabis and cocaine, Drug Alcohol Dependency, 115(1-2), 120-130.
Of course its possible!
40
o Irritability and/or anxietyo Insomniao Nausea / poor appetite
Typically occurs after heavy, prolonged use
Symptoms peak a few days / week following cessation of use
long-term health implications of cannabis use similar to not flossing41
Studies indicate that majority of recreational cannabis users do progress to harder drug use o Long-term probability and predictors from first time use to dependence: 1
67.5% - 22.7% -
20.9% - 8.9% -
Cannabis use amongst young teens (ages 12-17) has increased over the past decade, in spite of significantly increasing THC concentrations, , the prevailing view within this group that it is harmful, has 2
1 Meier, M.H. et al, Associations between cannabis use and physical health problems in early midlife: A longitudinal comparison of persistentcannabis versus tobacco users, JAMA Psychiatry, 37(70, 731-740.
2 Compton, W. Deputy Director, National Institute of Drug Abuse, Washington, D.C.; Presentation given at “Innovations in the Science of Cannabis Conference” McMaster University, Michael G. DeGroote Centre for Medical Cannabis Research. Feb 9th, 2018.
42
This does not in any way negate the fact that adolescent use of THC demonstrates altered brain function that may be permanent
Preteen and young adolescents are at special risk, and cannabis use of any kind should be clearly and strongly discouraged
43
In the Skinner Decision in Nova Scotia, an independent human rights tribunal ruled that a man suffering from chronic pain, with a medical cannabis Rx from his doctor, was required to have his cannabis covered by his employee benefit plan – ‘just like any other medicine’
Previously, Sun Life Insurance had agreed to cover medical cannabis for faculty, students, and employees at two large Ontario universities, based on index case by Jonathan Zaid
44
Last year, Loblaw’s, Canada's largest grocery retailer and pharmacy, with over 1,300 Shoppers Drug Mart stores, and 500 in-store pharmacies, announced they will be offering medical cannabis on a PA basis, employees suffering with cancer or MS… > 50,000 employees
CBC News Tuesday May 30th, 2017:
1 Benefits Canada; ‘Benefits & Pension Summit’; 201745
46
Medical cannabis coverage is rapidly becoming one of hottest topics in the employee benefits space
Most employers are struggling with cost-containment Biologics & specialty drugs Chronic disease (cancer, diabetes, CAD) Drug addiction – (methadone tx, collateral dz, counselling…) Economic loss associated with employee substance abuse:
Challenge to employers now becomes balancing sustainability of drug plans, against providing needed coverage for necessary treatments1 HR Daily Advisor; Combating Substance Abuse | Employee Benefit Programs; March 12, 2018 47
There is pressing need to take a very different look and approach to managing health / drug benefit plans….
Unsustainable to pay for everything today, , to pay for all new products and services as they launch
HOWEVER, it is this very lack of controls and monitoring that has greatly contributed to the opioid and Rx drug crisis issue today….
48
Many of the opioids on the street start off as a legitimate Rx
✘ So me and my colleagues are complicit
They are filled by a pharmacist
✘ So they are complicit
… and paid for by a private drug plan like yours
49
So either product is being diverted, or, some members of drug benefit plans are becoming more entrepreneurial
Plan sponsors have both a social / moral, as well as a fiscal / fiduciary obligation to your plans’ members, to better manage opioids While I’m not suggesting that medical cannabis is entire
solution, the less addictive, safer, and opioid-sparing properties can allow for greater cost controls, and significantly improved QoL for members 50
So either product is being diverted, or, some members of drug benefit plans are becoming more entrepreneurial
Plan sponsors have both a social / moral, as well as a fiscal / fiduciary obligation to your plans’ members, to better manage opioids National Safety Council Survey of >500 HR decision makers: 1
, “so that employees can avoid taking opioids”
1 National Safety Council Survey; http://www.nsc.org/NewsDocuments/2017/Media-Briefing-National-Employer-Drug-Survey-Results.pdf51
Opioids and other chronic pain meds Biologics and other high cost specialty (IBS) drugs
(e.g. Remicade®, Humira®, Cimzia® )… and more coming on line
Mental health medications
The benefits to an employer of instituting medical cannabis coverage on employee plan are:
Not to mention the downstream effects of all the iatrogenic disease by the above medications
52
Paramedical costs (physio, chiro, massage….) Mental health counselling Drug addiction counselling Absenteeism & Presenteeism
Additional benefits to an employer of instituting medical cannabis coverage on employee plans are:
53
Emphasis on CBD-predominant or ‘balanced’ formulations Truly medically-based & validated delivery systems
- MDIs, vaporizers, gel capsules, injectables, transdermals, sublingual sprays, gums, lozenges
HSA with annual limits allowing for allocated spend without need to limit clinical indications (healthcare discussion between MD | patient). Alternative is scaring patient away, and disease progression
Start with responsible and limited approach, and expand coverage over time
54
It is recognized that opioids - both those obtained through legal Rx means, as well as those obtained from ‘the street’ - are destroying lives, families, and some workplaces
Opioid-sparing effect of cannabinoids is becoming well-established, can reduce opioid abuse, save on pharmaceutical expenditure, and, may save on overall insurance costs
55
Public, employee and union pressure will increasingly demand insurance coverage for emerging cannabinoid medicines, as leading companies come onboard
Employers & insurers who are early adopters, will likely receive ‘first mover’ advantage, and be viewed as proactive force in combatting the opioid epidemic, and if early data and indicators hold, may enhance their own bottom lines
56
Insurers and plan sponsors must partner with socially responsible LPs, as a way to inform, educate and help safely manage plan member use
Employers must demand a commitment by industry to the development of superior evidence-based, cannabis medicines
57
STARSEED IS…A GLOBAL CANNABIS COMPANY
58